Depomed — Merger or Acquisition (December 2017)
13 slides from Depomed's merger presentation, Dec 4, 2017
Slide 1: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("Act"). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor"
Slide 2: A Clear Strategy for Growth
A Clear Strategy for Growth Executing on a Three Pillar Growth Strategy 3 MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Anno
Slide 3: Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA Franchise
Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA® Franchise Opioid Market Dynamics Demanded Evaluation of Multiple Options: Option 1: Grow into Current Pain Organization through Business Development Activity: Extensive analysis and discussion resulted in conclusion that differentiated
Slide 4: NUCYNTA Commercialization Agreement
NUCYNTA® Commercialization Agreement At closing, Collegium Pharmaceutical will obtain the rights to commercialize NUCYNTA® Depomed will retain ownership of the NDAs and be responsible for NUCYNTA® product supply Depomed will maintain responsibility for pediatric post-marketing studies Collegium will
Slide 5: Collegium: Ideal Partner to Take NUCYNTA to the Next Level
Collegium: Ideal Partner to Take NUCYNTA® to the Next Level Recognized as an emerging leader in pain management and committed to building a leading pain company Xtampza® ER is the fastest growing Extended Release branded opioid Strong home office, commercial and managed care infrastructures Salesfor
Slide 6: Headquarters Restructuring and Relocation Aligns with New Business Model
Headquarters Restructuring and Relocation Aligns with New Business Model Headquarters Relocation in 2018: Evaluating Mid-West and East Coast Sites Provides Improved Access to Pharmaceutical Talent Current Footprint: 60,000 square feet housing 120 employees 380 person salesforce New Footprint: Approx
Slide 7: Financial Overview
Financial Overview August Moretti SVP Finance and Chief Financial Officer
Slide 8: NUCYNTA Cash Flows and Reduction in Expenses Will Improve EBITDA and EBITDA Margins
NUCYNTA® Cash Flows and Reduction in Expenses Will Improve EBITDA and EBITDA Margins Transaction Provides Strong Cash Flows to Depomed from NUCYNTA® Sales In Connection with this Transaction, Depomed to Eliminate its Pain Salesforce and Terminate Brand Marketing Expense for NUCYNTA® Depomed to Reduc
Slide 9: Potential for EBIDTA Improvement
Potential for EBIDTA Improvement Assumed NUCYNTA Net Sales* 11 $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Grünenthal ($3.2) - $1.2 Net EBIDTA Improvement $46.8 $37 $25.2 Guidance to be Provided in 2018 *For illustrativ
Slide 10: Potential for EBIDTA Improvement
Potential for EBID Improvement Assumed NUCYNTA Net Sales* $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Griinenthal ($3.2) - $1.2 Net EBIDTA Improvement $46.8 $37 $25.2 *For illustrative purposes only Guidance to be Provi
Slide 11: Summary
Summary Arthur Higgins President and Chief Executive Officer
Slide 12: Delivering on Our Strategy for Growth and Creating Shareholder Value
Delivering on Our Strategy for Growth and Creating Shareholder Value 14 MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Announ
Slide 13: Delivering on Our Strategy for Growth and Creating Shareholder Value
Delivering on Our Value : ooU GROW Neurology and Pain Businesses BUILD a New Specialty Business Cosyntropin/Depot Transaction Announced November 2017 Seoeromen